Cftr Trikafta denied as not medically necessary by CVS Caremark?

Trikafta covered for FDA-labeled mutations + CF center attestation. Symdeko/Orkambi non-preferred when Trikafta-eligible.

CFF 2023 Modulator Recommendations + CFTR2 database for non-F508del responsive variants. April 2023 FDA expansion to age 2-5 (VX20-445-111). Step-therapy through inferior modulator contradicts CFF first-line Trikafta recommendation.

## Why CVS Caremark Denies Trikafta on Medical-Necessity Grounds

CVS Caremark, acting as pharmacy benefit manager for many commercial and employer plans, applies clinical coverage criteria before authorizing dispensing of high-cost specialty drugs. A medical-necessity denial for this CFTR modulator combination means the submitted clinical information did not satisfy one or more of the criteria in CVS Caremark's (or the underlying plan's) coverage policy — most commonly: incomplete documentation of the confirmed CFTR genotype, insufficient clinical severity documentation, or a missing or inadequate prescriber medical-necessity statement. These gaps are fixable. The therapy has strong clinical backing and a well-defined eligible population.

## Your Federal Appeal Rights

Under ACA §2719, non-grandfathered plans must provide at least one internal appeal and access to external independent review. Under ERISA §503, employer-sponsored plans must provide full-and-fair review. You have 180 days from the denial notice to file an internal appeal. After an internal denial, external review is available — typically within four months. Expedited review (often 72 hours) is available when standard timelines would jeopardize health.

## The Concrete Appeal Process

1. Request the denial explanation and CVS Caremark's clinical coverage criteria — the denial letter must specify which criterion was not met. 2. Work with the prescribing provider to assemble a complete, criteria-responsive documentation package. 3. File a written internal appeal within the deadline on the denial letter, with all supporting documentation attached. 4. If denied internally, request external independent review through the IRO process described in the denial letter.

## Documentation to Gather

• Confirmed CFTR genotype report from a certified laboratory, identifying both mutations by name
• Pulmonary function testing results with longitudinal trend data reflecting disease trajectory
• Exacerbation and hospitalization history with dates and clinical details
• Current clinical notes from a CF specialist or treating pulmonologist documenting symptom burden and functional status
• Prior treatment history with agent names, dates of use, and documented responses or reasons for discontinuation
• Prescriber's medical-necessity letter that maps each coverage criterion to a specific chart finding, references the FDA-approved prescribing information, and cites the applicable Cystic Fibrosis Foundation clinical care guideline

## Criteria-Mapping Structure

Obtain CVS Caremark's published clinical coverage policy for this drug class. Build a direct, criterion-by-criterion response:

| Coverage Criterion | Supporting Chart Evidence | |---|---| | Confirmed eligible CFTR genotype | Genetics lab report — lab, date, result | | Diagnosis of cystic fibrosis | Chart confirmation, sweat chloride or genetic diagnosis on file | | Clinical severity or functional status | PFT trend, exacerbation log, clinical notes | | Prescriber is CF specialist or coordinating with one | Provider credentials and care team documentation | | Prior therapy history (if required) | Medication list with dates and outcomes |

The prescriber letter should not be generic — it should address each criterion by name and cite the specific chart documentation that satisfies it. A generic letter is the most common reason a complete documentation package still results in a second denial.